News
Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced ...
$5 Million in Funding: In April 2025, Serina secured $5 million from strategic shareholders to support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback